Clinical evaluation is one of the most error-prone stages in medical device registration – choosing the wrong route can mean multiple rounds of deficiency letters at best, or starting over from scratch at worst. Based on the current Provisions for Medical Device Registration and Filing (NMPA Order No. 47) and the series of clinical evaluation guidance documents issued by the Center for Medical Device Evaluation (CMDE), this article outlines the applicable conditions, evidence requirements, and frequently asked questions for the three clinical evaluation routes, helping companies choose the right route at the project initiation stage.
1. Regulatory Framework: Three Routes, One Bottom Line
Under Article 26 of the Regulations on the Supervision and Administration of Medical Devices (State Council Order No. 739) and the Provisions for Medical Device Registration and Filing, there are three routes for medical device clinical evaluation:
| Route | Applicable Conditions | Core Evidence |
|---|---|---|
| Clinical exemption | The product is listed in the Catalogue of Medical Devices Exempt from Clinical Evaluation, and is consistent with the catalogue description | An item-by-item comparison between the product under registration and the corresponding catalogue entry |
| Same-device clinical evaluation | Equivalence can be argued through a device of the same variety already on the market in China | Same-device comparison, evidence addressing the differences, clinical literature and data |
| Clinical trials | Neither of the first two routes is feasible, or the difference evidence is insufficient to demonstrate safety and effectiveness | Clinical trial data generated and conducted in accordance with the medical device GCP |
There is only one bottom line: the clinical evaluation documents must cover the entire intended use stated in the product technical requirements and the instructions for use, and must be consistent with the actual state of the product. This is exactly the “consistency with the actual state” principle repeatedly emphasized in the Technical Guidance Principles for Medical Device Clinical Evaluation.
2. Clinical Exemption Route: Compare Against the Catalogue, Not Just the Product Name
The core action for the clinical exemption route is an item-by-item comparison between the product under registration and the relevant entry in the Catalogue of Medical Devices Exempt from Clinical Evaluation: the product name, structural composition, and intended use must all be consistent with the catalogue description.
Frequent issues include:
- The product name differs from the catalogue entry but is substantively identical: it is advisable to simultaneously request a classification determination or a catalogue comparison opinion, and keep written evidence on file;
- The structural composition includes components not covered by the catalogue entry: the additions beyond the catalogue must be argued separately, and where such argumentation is not possible, the same-device route should be taken;
- The intended use is written too broadly: intended uses beyond the scope described in the catalogue entry are not eligible for the clinical exemption route.
For products under the exemption route, submitting a “comparison statement against the catalogue” is sufficient, but the comparison must go down to the level of structure and performance specifications – it cannot stop at matching product names.
3. Same-Device Route: Equivalence Argumentation Is the Center of All the Work
The legal basis for same-device clinical evaluation is the Technical Guidance Principles for Equivalence Argumentation in Medical Device Clinical Evaluation. The argumentation must proceed along three dimensions:
- Intended use comparison: intended purpose, applicable population, use environment, method of use, and contraindications compared item by item;
- Technical characteristics comparison: working principle, structural composition, materials, performance specifications, software and algorithms, etc.;
- Biological properties comparison: contact sites, contact manner, and biocompatibility strategy.
Key rule: the existence of differences does not mean the same-device route is unavailable. Evidence must be submitted item by item for each difference – comparative laboratory testing, literature data, or non-clinical studies – to demonstrate that the difference does not affect safety and effectiveness. Only the parts that cannot be argued with sufficient evidence are where supplementary clinical trial data are needed.
Frequent deficiency reasons include: the registration certificate of the same device has expired, the comparison data come from a product marketed overseas rather than one already on the market in China, and the literature search does not state the search strategy or the inclusion and exclusion criteria. The literature search must be documented in accordance with the Technical Guidance Principles for Writing Medical Device Clinical Evaluation Reports so that it is “reproducible”.
4. Clinical Trial Route: Protocol Design Determines the Outcome of the Application
High-risk Class III devices (such as novel implants and innovative software algorithm products) mostly require the clinical trial route. Under the Quality Management Practices for Medical Device Clinical Trials:
- Trials must be conducted at filed clinical trial institutions with the required qualifications;
- The trial protocol must specify the primary endpoints, the basis for the sample size, and the evaluation time points;
- Filing must be completed on the CDE clinical trial filing platform before the trial is conducted;
- For products involving new technologies or new algorithms, early communication with CMDE is recommended (through the innovative device review pathway or pre-submission meetings).
Clinical trial protocol design should be approached “in reverse” – derive the protocol endpoints from the evidence requirements of the registration review, rather than from commercial marketing points.
5. Three Preparations on the Company Side
- Fix the route at project initiation: the clinical evaluation route should be locked in at the project initiation stage, to avoid discovering evidence gaps only after the design is finalized;
- Screen candidate same devices early: already on the market in China, with a valid registration certificate, and with accessible documentation – all three are indispensable;
- Build the evidence chain in parallel: design non-clinical test items to a depth at which the data can be cited in the clinical evaluation.
Choosing a clinical evaluation route is, in essence, an engineering trade-off between “evidence cost” and “review certainty”. Choosing the right route and reserving sufficient evidence is the first safeguard for approval of a registration project on schedule.
This article is a general overview of clinical evaluation routes and does not replace product-specific regulatory judgment or review communication. When filing, the route should be determined in light of the latest catalogue, product-specific guidance documents, and CMDE requirements.